XBIT 250117 12.50C (XBIT250117C12500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

XBIT250117C12500

Watchlist

0.00
0.000.00%

15min DelayTrading Jan 13 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

XBiotech Inc.'s (NASDAQ:XBIT) Largest Shareholders Are Individual Investors With 49% Ownership, Insiders Own 35%
Yahoo FinanceJan 10 10:50 ET
XBiotech Appoints Renowned Scientist to Board of Directors
TipRanksDec 31 15:47 ET
Is XBiotech (NASDAQ:XBIT) A Risky Investment?
Simply Wall StDec 24, 2024 05:33 ET
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT NewswiresDec 23, 2024 14:00 ET
Express News | XBiotech Shares Resume Trade
BenzingaDec 23, 2024 09:52 ET
XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings
BenzingaDec 23, 2024 09:03 ET

Comments

Trytosaveabit

Dec 23, 2024 08:09

$XBiotech (XBIT.US)$ XBiotech Halts Rheumatology Program After Phase II Rheumatoid Arthritis Study Fails To Meet Primary Endpoint Amid Data Irregularities; Future Studies On Hold Pending Further Analysis Of Findings

Stock Region

Jun 21, 2024 10:19

Biotechnology Company Announces Promising Data From Advanced Pancreatic Cancer Study

XBiotech's Phase 1/2 Study on Advanced Pancreatic Cancer: A Detailed Review.
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...

Jaguar8

Jun 18, 2024 12:04

NEWS

$XBiotech (XBIT.US)$
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...

Moomoo AI

Nov 14, 2023 08:07

XBiotech believes that Natrunix will be a breakthrough therapy for rheumatological diseases. The company is eagerly anticipating the results of the Phase II study. Dr. Kivitz expressed excitement in investigating a novel approach towards treating Rheumatoid Arthritis through Natrunix.

Press Release: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

54088 FROM RWS

Jul 29, 2021 19:25

$XBiotech (XBIT.US)$
Where can check this information?
If I have 10 share....
Where is the money? 🧐